Vaxcyte Q4 2023 GAAP EPS $(1.82) Misses $(1.07) Estimate
Portfolio Pulse from Benzinga Newsdesk
Vaxcyte (NASDAQ:PCVX) reported a Q4 2023 GAAP EPS loss of $(1.82), missing the consensus estimate of $(1.07) by 70.09%.
February 27, 2024 | 9:09 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Vaxcyte reported a Q4 2023 GAAP EPS loss of $(1.82), missing the consensus estimate of $(1.07) by 70.09%.
Vaxcyte's significant miss on the Q4 2023 GAAP EPS estimate indicates potential underlying issues or challenges that the company may be facing, which could negatively impact investor confidence and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100